NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

A large deal will need a multi-party partnership. At this stage there’s still too much risk for one BP to shell out for a $30+ billion deal.

But it’s not too much risk for let’s say three separate partners to shell out $10 billion each in return for a share of the patient revenue streams; licensing fees for combo trials; and appreciation of their equity interest.

The partnership has been in the works for at least three years. So all systems are go for next week, or no later than the following.